Chris Holmes, Ph.D.VICE PRESIDENT, CMC OPERATIONS
Dr. Holmes joined as Vice President, CMC Operations in October 2017. Prior to joining Apellis, Chris was an independent Chemistry, Manufacturing, Controls (CMC) consultant specializing in PEGylated peptide and oligonucleotide conjugates. Previously, he was Vice President of Chemical and Pharmaceutical Development at Regado Biosciences, Executive Director at Affymax, and Director of Chemistry at Glaxo Welcome. While at Affymax, Chris was the inventor and subject matter expert (SME) on Omontys™, the only PEGylated synthetic peptide approved by the FDA. Chris has extensive experience in regulatory writing, process and pharmaceutical development, discovery research, medicinal chemistry, combinatorial chemistry, solid phase synthesis, photochemistry, and technology development. Chris is an inventor on 32 US patents and has authored over 50 scientific papers. Chris obtained his Ph.D. in synthetic organic chemistry from UC Berkeley and completed his postdoctoral training in bioorganic chemistry at Stanford University.